---
title: "The Surprise That Sent Vertex — And Its Chief Rival — Soaring"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299802338.md"
description: "On Tuesday, Vertex saw a notable increase in its stock value, while Maze Therapeutics experienced a significant surge in their shares, due to an unexpected expansion of their kidney disease drug portfolio. This unexpected development caused Vertex's stock to rise, and Maze Therapeutics' shares to skyrocket. The specific figures detailing the increase in stock prices and market capitalization were not disclosed in the report."
datetime: "2026-09-22T18:10:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299802338.md)
  - [en](https://longbridge.com/en/news/299802338.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299802338.md)
generator: "portal-rs"
---

# The Surprise That Sent Vertex — And Its Chief Rival — Soaring

On Tuesday, Vertex saw a notable increase in its stock value, while Maze Therapeutics experienced a significant surge in their shares, due to an unexpected expansion of their kidney disease drug portfolio. This unexpected development caused Vertex's stock to rise, and Maze Therapeutics' shares to skyrocket. The specific figures detailing the increase in stock prices and market capitalization were not disclosed in the report.

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [MAZE.US](https://longbridge.com/en/quote/MAZE.US.md)

## Related News & Research

- [Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $202,920.75](https://longbridge.com/en/news/300722738.md)
- [2 Healthcare Stocks That Just Delivered Great News for Investors](https://longbridge.com/en/news/300206760.md)
- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria](https://longbridge.com/en/news/299770014.md)
- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**